Dr. Allen L. Cohn, MD

Dr. Cohn practices at Rocky Mountain Cancer Centers in Denver, Colorado.

Dr. Cohn's NPI, 1316921976, was assigned on December 6, 2005. Dr. Cohn graduated from University of Maryland School of Medicine in 1985. Dr. Cohn holds Colorado license DR.0027525.

Dr. Cohn's primary practice is Rocky Mountain Cancer Centers, at 1800 N Williams St, Denver, CO 80218 in Denver County. The practice phone is (303) 930-7800.

Dr. Cohn's primary practice is Rocky Mountain Cancer Centers in Denver, Colorado. Dr. Cohn is also affiliated with HCA HealthONE Rose. The medical group on file is Rocky Mountain Cancer Centers. Dmand AI also links Dr. Cohn to 4 more hospitals, 2 group practices and clinics and 1 medical group, each named with a free account.

Dmand AI tracks the electronic health record (EHR) system at each site where Dr. Cohn practices, 7 sites in all. Vendor and product names are available with a free account.

Hematology and oncology is Dr. Cohn's primary specialty in the NPI Registry, under taxonomy code 207RH0003X. Dr. Cohn is licensed in Colorado.

CMS data shows 16,768 Medicare services from Dr. Cohn across 43 procedure codes in 2024, for 536 Medicare patients. Medicare paid $690,603 for them.

CMS counts 536 Medicare patients who saw Dr. Cohn in 2024. The largest group is 65 to 74, with 254 patients. 65% of them have cancer, and 63% have high blood pressure. 7% are also on Medicaid. Their average risk score is 1.95, where 1.00 is the Medicare average, so they are sicker than most Medicare patients.

Across all payers, Dmand AI patient panel data puts Dr. Cohn's median patient age at 71, with 52% women.

In 2024, Dr. Cohn wrote 758 Medicare Part D claims for 132 patients. 77% of them were for generic drugs. CMS names the drug for 484 of them, across 22 drugs with 11 or more claims each, at $497,720 in total drug cost. In 2023, CMS named 497 claims across 21 drugs.

Dr. Cohn accepts Medicare assignment, so Medicare's approved amount is taken as full payment.

Dmand AI links 42 papers to Dr. Cohn, published from 2008 to 2024. 2016 was the busiest year, with 4. The most frequent topics are Antibodies, Monoclonal, Humanized, Antineoplastic Combined Chemotherapy Protocols and Colorectal Neoplasms. Dr. Cohn has published most often in Ann Oncol. Dr. Cohn's most frequent co-authors are Donald Anthony Richards, MD, Marcia S. Brose, MD and Carol Aghajanian, MD.

Dmand AI links Dr. Cohn to 12 clinical trials, 3 of them phase 3 studies. 3 are still active or recruiting. Conditions studied include Rectal Diseases, Colorectal Neoplasms and Melanoma. Bristol-Myers Squibb sponsors the most, 2. Open Payments lists research payments to Dr. Cohn that name 3 trials.

CMS Open Payments shows 161 general payments to Dr. Cohn from 32 drug and device companies from 2016 to 2025. Consulting fees make up the largest share, 52% of the total. Bristol-Myers Squibb Company paid the most, $12,526. It also lists 7 research payments totaling $128,101 from 2016 to 2021, naming 3 clinical trials.

Dr. Cohn graduated from University of Maryland School of Medicine in 1985.